Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin 81 mg vs 162 mg for Preeclampsia Prevention
NCT04158830Phase 4Withdrawn
- Sponsor
- University of Tennessee
- Start
- Jun 2020
- Primary completion
- Nov 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aspirin in preeclampsia (2 arms), sponsored by University of Tennessee. Primary endpoint: Occurrence of Preeclampsia at 30 weeks. Planned start Jun 2020; status: withdrawn.
02
Drugs
aspirin
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NCT04158830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04158830.